Abstract The discipline of Cardio-Oncology has seen tremendous growth over the past
decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the …

Aims The risk and incidence of cardiovascular (CV) immune-related adverse events (irAEs)
associated with immune checkpoint inhibitors (ICIs) in cancer patients remain unknown …

Over the last decade or so, there has been a paradigm shift in the oncologic care of patients
with a range of solid tumour and haematologic malignancies, away from traditional cytotoxic …

A retrospective multicenter registry including 49 institutions and 11 countries was built using
a Research Electronic Data Capture web-based platform with Institutional Review Board …

Cardiovascular disease and cancer are the leading causes of morbidity and mortality in the
US. Despite the significant progress made in cancer treatment leading to improved …

The broad application of immune checkpoint inhibitors (ICIs) has led to significant gains in
cancer outcomes. By abrogating inhibitory signals, ICIs promote T cell targeting of cancer …

Abstract Background Immune checkpoint inhibitors (ICIs) are a central part of cancer
therapy; however, cardiac complications, such as myocarditis, have the potential for …

Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events
including myocarditis, whilst improving cancer-related outcomes. There is thus a clinical …

Introduction Immune therapy has ushered in a new era of tumor treatment, at the expense of
immune-related adverse events, including rare but fatal adverse cardiovascular events, such …

Background and Objective Immune checkpoint inhibitor (ICI)-associated myocarditis is a
fatal immune-related adverse events (irAEs), which is prone to affecting multiple organ …